Literature DB >> 1442475

Update on hormone replacement therapy.

R D Gambrell1.   

Abstract

The well-recognized benefits of hormone replacement therapy include relief of vasomotor symptoms, alleviation of psychogenic manifestations, prevention of atrophic vaginitis, prevention and treatment of osteoporosis, and prevention of cardiovascular disease. Risks can be minimized by proper evaluation and appropriate hormone replacement. When an adequate dosage of estrogen is given, the added progestogen does not adversely affect lipid levels. When progestogens are added to estrogen replacement therapy, the incidence of endometrial cancer is lower in postmenopausal women receiving this form of therapy than in untreated postmenopausal women. Although the risk of breast cancer is a matter of controversy, it does not seem to increase with estrogen therapy; the addition of progestogen may decrease the risk for some women. The prognosis for breast cancer is improved in women receiving hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1442475

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

1.  Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study.

Authors:  S Stallard; J C Litherland; C M Cordiner; H M Dobson; W D George; E A Mallon; D Hole
Journal:  BMJ       Date:  2000-02-05

2.  Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit.

Authors:  C Harding; W F Knox; E B Faragher; A Baildam; N J Bundred
Journal:  BMJ       Date:  1996-06-29

3.  Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium.

Authors:  K L Bruner; W H Rodgers; L I Gold; M Korc; J T Hargrove; L M Matrisian; K G Osteen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

4.  Hyperlipidemia and obesity among diabetics at jubail miiltary hospital.

Authors:  K S Al-Ghamdi; R Rehman
Journal:  J Family Community Med       Date:  1998-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.